Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
C. K. Brierley, B. H. Yip, G. Orlando…·A. J. Mead
The paper identifies chromothripsis-induced amplification of DYRK1A in blast phase MPN as a driver of aggressive disease and a potential therapeutic target.
M. D. Kinnaman, S. Zaccaria, A. Makohon-Moore…·C. A. Iacobuzio-Donahue
This study identifies subclonal copy number alterations in relapsed osteosarcoma, showing MYC gain/amplification in treatment-resistant clones and their emergence before chemotherapy.
B. T. Diamond, B. Ziccheddu, K. H. Maclachlan…·F. Maura
The paper reconstructs the evolutionary history of therapy-related myeloid neoplasms using chemotherapy-associated mutational signatures and identifies distinct mutational patterns linked to different chemotherapies.
A. Schnegg-Kaufmann, J. A. I. Thoms, G. S. Bhuyan…·J. E. Pimanda
This study examines the contribution of mutated hematopoietic stem and progenitor cells to blood cell populations in MDS and CMML before and after AZA treatment.
H. J. Landau, V. Yellapantula, B. J. Diamond…·F. Maura
This study uses whole genome sequencing to show that relapsed multiple myeloma exhibits accelerated systemic seeding driven by chemotherapy-induced mutations and clonal expansion of single myeloma cells.
J. J. Harding, M. A. Lowery, A. H. Shih…·A. M. Intlekofer
The paper identifies isoform switching between mutant IDH1 and IDH2 as a mechanism of acquired resistance to IDH inhibitors in cancers.